Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIGMA-06G
- Development stage
- Preclinical
- Lead developer
- Filamon
- Modality
- Small Molecules
01
Overview
SIGMA-06G is a first-in-class small molecule therapeutic candidate under development by Filamon for the treatment of dry age-related macular degeneration (dry AMD), including both early-stage disease and late-stage geographic atrophy. Developed under Filamon's proprietary SIGMA platform, the drug is designed to target proteins susceptible to oxidative damage and free radical production, which predisposes them to abnormal, self-propagating, and toxic 'prion-like' misfolding and aggregation. By binding to and inactivating these misfolded proteins, SIGMA-06G aims to deliver dual anti-inflammatory and anti-degenerative therapeutic effects to preserve photoreceptor cells and prevent vision loss.
Beyond the preview
Go deeper on SIGMA-06G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIGMA-06G.